Trever G. Bivona

Trever G. Bivona

Oncology
1233 York Ave
Apt 6L
New York, NY 10065

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 145 publications

Challenges and advances in drug resistance and tolerance in cancer.

Challenges and advances in drug resistance and tolerance in cancer.

Journal: Journal of experimental & clinical cancer research : CR
Published: January 21, 2026

Targeting BRAF Class II and III Mutations in NSCLC with the pan-RAF inhibitor Exarafenib Reveals ARAF-KSR1-Mediated Resistance and Rational Combination Strategies.

Targeting BRAF Class II and III Mutations in NSCLC with the pan-RAF inhibitor Exarafenib Reveals ARAF-KSR1-Mediated Resistance and Rational Combination Strategies.

Journal: Research square
Published: November 24, 2025

CDK4 or CDK6 upregulation induces DNA replication stress and genomic instability to cause EGFR targeted therapy resistance in lung cancer.

CDK4 or CDK6 upregulation induces DNA replication stress and genomic instability to cause EGFR targeted therapy resistance in lung cancer.

Journal: bioRxiv : the preprint server for biology
Published: November 19, 2025

Pan-RAF inhibitor exarafenib targets BRAF class II/III NSCLC and reveals ARAF-KSR1 resistance and combination strategies.

Pan-RAF inhibitor exarafenib targets BRAF class II/III NSCLC and reveals ARAF-KSR1 resistance and combination strategies.

Journal: Nature communications
Published: October 07, 2025

In vivo manipulation of the protein homeostasis network in rhabdomyosarcoma.

In vivo manipulation of the protein homeostasis network in rhabdomyosarcoma.

Journal: Oncotarget
Published: August 29, 2025

Reversible therapeutic resistance in EGFR mutant lung cancer caused by RB1 loss induced lineage plasticity.

Reversible therapeutic resistance in EGFR mutant lung cancer caused by RB1 loss induced lineage plasticity.

Journal: bioRxiv : the preprint server for biology
Published: August 13, 2025

BRAFV600E-Driven Lung Tumorigenesis Requires Ligand-Mediated Activation of ERBB Receptor Signaling.

BRAFV600E-Driven Lung Tumorigenesis Requires Ligand-Mediated Activation of ERBB Receptor Signaling.

Journal: bioRxiv : the preprint server for biology
Published: July 14, 2025

Small-molecule activation of the tumor suppressor kinase LKB1 via the pseudokinase STRAD.

Small-molecule activation of the tumor suppressor kinase LKB1 via the pseudokinase STRAD.

Journal: Cell chemical biology
Published: June 04, 2025

FET Fusion Oncoproteins Disrupt Physiologic DNA Repair and Create a Targetable Opportunity for ATR Inhibitor Therapy.

FET Fusion Oncoproteins Disrupt Physiologic DNA Repair and Create a Targetable Opportunity for ATR Inhibitor Therapy.

Journal: Cancer research
Published: May 20, 2025

Drug resistant cancer cells show increased nuclear mechanotransduction and mechanically targetable YAP-regulated vulnerability.

Drug resistant cancer cells show increased nuclear mechanotransduction and mechanically targetable YAP-regulated vulnerability.

Journal: Biomaterials
Published: May 09, 2025

Acquired resistance in cancer: towards targeted therapeutic strategies.

Acquired resistance in cancer: towards targeted therapeutic strategies.

Journal: Nature reviews. Cancer
Published: April 14, 2025

Condensates as a Culprit in RAS Activation and Inhibitor Resistance.

Condensates as a Culprit in RAS Activation and Inhibitor Resistance.

Journal: Cancer research
Published: March 03, 2025
Showing 1-12 of 145

Last Updated: 09/26/2026